ICLE 2026 (International Conference on Lymphocyte Engineering) — 6th International Conference on Lymphocyte Engineering

Basic Event Details

• Dates: 15–17 July 2026
• Venue: Milan, Italy (conference location in Milan as stated on the official event page)
• Event theme: “Advancing immune-gene therapy across diseases”
• Core focus: lymphocyte engineering, immune-gene and cell therapy, gene therapy and genome engineering, and immunotherapy translation from research to clinical practice

1️⃣ Who attends (BUYERS / ATTENDEES)

ICLE 2026 is a scientific and translational medicine conference focused on immune-gene therapy and lymphocyte engineering. As a result, the attendee mix is typically a blend of academia, clinicians, translational scientists, research institute leaders, industry R&D, and commercial stakeholders supporting the development, translation, and manufacturing ecosystem for cell/gene therapies.

Primary attendee groups we expect to see:

• Academic & translational researchers in lymphocyte engineering, immune-oncology, adoptive cell therapies, and genome engineering
• Clinical leaders and clinician-scientists working on CAR T-cell and related cell therapy programs, including solid tumor initiatives
• Biotech/biopharma R&D teams focused on cell therapy pipelines (discovery → preclinical → clinical), translational biomarkers, and clinical program execution
• Manufacturing & process development stakeholders (when present) supporting the translation of engineered cells into clinical-grade workflows
• Industry solution providers that support the ecosystem around cell/gene therapy development (tools, assays, enabling technologies, quality/regulatory support, CRO-like translational services, and partnering organizations)
• Invited speakers & poster presenters representing global institutions advancing immune-gene therapy and lymphocyte engineering

For attendee-list targeting, the “buyer” layer is most often concentrated in scientific leadership, translational program leadership, platform/technology leads, and corporate innovation/business development roles—people who influence vendor selection for research/clinical-enabling solutions.

2️⃣ Where the show is happening + attendee geographic origin

Where the show is happening: Milan, Italy (15–17 July 2026), per the official event site content.

Attendee geographic origin (how it typically behaves for an international translational conference):

• Strong international presence due to the conference’s stated global scientific positioning and international expert participation
• Europe-heavy participation is expected because Milan hosts a dense life sciences and biotech ecosystem and the conference is held in Italy
• North America participation is also expected given the prominence of CAR T/CAR T-adjacent translational work in the US and Canada
• Additional global reach (Asia-Pacific, Israel/Middle East, etc.) is plausible because the program highlights international speakers and a worldwide community

Our recommendation for geographic targeting is: Europe (Italy, Germany, UK, France, Benelux, Switzerland, Spain) + North America, with controlled expansion to Israel/Middle East and Asia-Pacific based on the client’s preferred customer profile.

3️⃣ Audience reach (Local / National / Global)

ICLE is positioned as an international conference with a field-specific focus (lymphocyte engineering and immune-gene therapy translation). While Milan is the physical location, the audience reach is fundamentally global because the theme, speaker profile, and translational domain attract international research and development stakeholders.

In practical terms, we classify ICLE as global in reach: the conference aims to bring experts together across borders to collaborate on translation, clinical practices, and emerging technologies.

4️⃣ Sample buyer company names (BUYERS ONLY) + Websites

Below are sample buyer-style companies that commonly align with lymphocyte engineering, CAR T-cell therapy ecosystems, immunotherapy translation, enabling technologies, and cell/gene therapy R&D/clinical support. These are intended as starter accounts for outreach and attendee-list targeting workflows.

Buyer target sample table (15–20 accounts)

Important: the highest-quality buyer list we can generate depends on your product category (tools/assays, manufacturing/CDMO services, software/data platforms, CRO services, regulatory/compliance, etc.). If we know the client’s website, we can narrow the titles and company segments to the most “purchase-likely” accounts.

5️⃣ Job profiles, industries & event type

Best job profiles to target

• Translational Research Leadership: Director/Head of Translational Science, Translational Medicine Lead
• Cell Therapy Program Leadership: Program Director, Cell Therapy Platform Lead, CAR T Program Lead
• Scientific Platform & Technology Owners: Genome Engineering Lead, Lymphocyte Engineering Platform Director
• Clinical Translation & Medical Affairs: Clinical Program Director (Cell Therapy), Head of Clinical Science for engineered cell modalities
• Business Development / Partnerships: BD Director for Cell & Gene Therapy, Strategic Partnerships Lead (industry technology collaborations)
• Bioprocessing & Manufacturing (if relevant to your offering): VP/Director Cell & Gene Therapy Manufacturing, Process Development Lead, Tech Transfer Lead
• R&D Operations / Vendor Evaluation: Procurement decision influences, Scientific Procurement, Supplier Quality/Technical Evaluation (only when your product fits)

Event type

ICLE 2026 is best categorized as a specialized life sciences / translational immunotherapy and cell & gene therapy scientific conference. Its agenda structure (program highlights, abstracts, keynote speakers, poster presentations, and sponsor visibility) indicates a hybrid of research dissemination and industry translation/partnership engagement.

6️⃣ Estimated attendance (expected total footfall)

The official website content provided does not state a total attendance number. For field-specific international translational conferences like this, a realistic expectation is often in the range of a few hundred to around 1,000+ attendees, depending on sponsorship scale and abstract volume.

Working estimate we would apply: ~500–900 attendees across 3 days, with the highest density among research presentations, keynote sessions, and sponsor/industry engagement windows.

Once we get additional info from your side (or your desired “buyer density” threshold), we can recommend the tightest attendee targeting strategy (e.g., translational science titles vs. broad scientific attendance).

7️⃣ Key focus areas & buyer engagement

Key focus areas (as indicated directly by the official theme and conference positioning):

• Immune-gene therapy across diseases
• Lymphocyte engineering and engineered immune cell strategies
• Gene therapy, cell therapy, and genome engineering
• Immunotherapy translation from basic research to clinical practice
• CAR T-cell therapy in solid tumors (explicitly referenced in the webinar topic listed on the site)
• Emerging lymphocyte engineering technologies and how collaborators solve translation challenges
• Collaboration-building across a global community of translational medicine scientists

How buyers are likely to engage:

• During keynote and highlight sessions: to identify scientific direction and validate where the field is going
• Through poster sessions & abstracts: to meet authors who represent internal discovery-to-translation pipelines
• With sponsors/exhibitors: to evaluate enabling technologies, tools, services, and partnership opportunities
• Via networking and informal meetings: to find collaborative paths aligned with clinical timelines

8️⃣ Client-product fit note + we need your client website

We can absolutely refine the “best buyers” selection for ICLE 2026, but we must align to your client’s product category and intended buying function. The official event site you shared provides strong thematic direction, yet the correct buyer set changes substantially depending on whether your client sells:

• Research tools/assays (cell analysis, screening, sequencing, immune profiling, phenotyping)
• Manufacturing/process technologies (bioprocessing, vectors/workflows, GMP-relevant solutions)
• Software/data platforms (biomarkers, clinical data integration, translational analytics, workflow automation)
• Services (CRO/CPO/translational research support, regulatory strategy, quality/compliance)
• Cell therapy-enabling reagents or consumables

Please share your client website URL (and if possible, a 1–2 sentence description of what they sell). After we review it, we will return:

• the best buyer company segments for ICLE 2026 (more precise than the starter accounts above)
• the best job titles most likely to be involved in purchase decisions
• a prioritized buyer list (so you can focus outreach and lead qualification)

9️⃣ Industry suggestions (mapped to an Apollo-like industry approach)

Using the industry taxonomy you provided, the most relevant filters for ICLE 2026 typically concentrate in life sciences, research, healthcare-adjacent, and technical R&D ecosystems. The best matching industries to use for buyer discovery are:

• Pharmaceuticals
• Biotechnology
• Research
• Medical Devices (only if your client’s offering is device/tooling oriented)
• Hospital & Health Care (only when your client sells into clinical sites/hospitals)
• Hospitality is not relevant—excluding it is usually better
• Medical Practice (only for healthcare provider-side offerings)
• Information Technology & Services (only if your client sells software/data platforms into translational research)
• Computer Software (if your product is a software platform for translational analytics/workflows)
• Outsourcing/Offshoring (if your client is an outsourced R&D/CRO-style provider)

If we know your client website, we can narrow this to the tightest 3–5 industries so the buyer list is higher-quality and closer to actual event relevance.

Next Step (so we can finalize the “best buyers” for your client)

Please send:

• Client website URL
• What the product/service is (1–2 sentences)
• Who buys internally (R&D, translational, manufacturing, procurement influence, BD/partnerships, etc.)
• Preferred geographies (EU only, US+EU, global)

Then we will finalize a targeted ICLE 2026 buyer plan with the most relevant company types and job titles.